From: Socio-economic drivers of drug-resistant tuberculosis in Africa: a scoping review
Characteristics | N | % | Citation |
---|---|---|---|
Mean age | 33, 7 | – | |
Sex | |||
 Male | 276,751 | 66,9 | [19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36, 38,39,40] |
 Female | 137,025 | 33,1 | [19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36, 38,39,40] |
Type of DR TB | |||
 RR/ MDR | 2173 | 0,5 | [19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35, 38, 39] |
 PRE- XDR | 104 | 0, 03 | [19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35, 38, 39] |
 XDR | 330 | 0,08 | [19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35, 38, 39] |
Mono drug resistance (other than RIF) | 136 | 0,03 | [19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35, 38, 39] |
Poli drug resistance) | 18 | 0,004 | [19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35, 38, 39] |
STB/ controls | 2473 | 0,5 | [19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35, 38, 39] |
DRTB type not indicated (no breakdown) | 408,542 | 98,7 | |
Duration of study – Average duration of studies | 32 months | – | [19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40] |
Treatment outcomes | |||
 Favourable (Cured/ Treatment completed) | 89,410 | 21,60 | |
 Unfavourable (Died/ Defaulted/ LTFU/ Failed/ relapse) | 66,063 | 15, 96 | |
 Transferred out | 8 | 0,002 | [31] |
 Treatment outcome not evaluated in study | 258,295 | 62,42 |